Catalyst Pharmaceuticals: Wachstumsstarker Spezialist für seltene Krankheiten
Erfolgreich mit Orphan Drugs: Catalyst punktet mit margenstarken Nischenprodukten wie FIRDAPSE und dem Wachstumstreiber AGAMREE. Starkes Quartal, zögernder Konsens:…
22,490€
1,81%
Echtzeit-Aktienkurs Catalyst Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Catalyst Pharmaceuticals Inc. Aktie
Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts
…
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a…
Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE
…
Catalyst Pharmaceuticals: Agamree Is Its Key To A Sustainable Future
…
Catalyst Pharmaceuticals executive sells shares worth $272,654 By Investing.com
Catalyst Pharmaceuticals executive sells shares worth $272,654…
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a…
Zacks.com featured highlights include Barrick Gold, Catalyst Pharmaceuticals, Allegiant Travel and America Movil
Barrick Gold, Catalyst Pharmaceuticals, Allegiant Travel and America Movil are part of the Zacks Screen of the Week article.…
Catalyst Pharmaceuticals: High Valuation Amid Weak Long-Term Prospects (Rating Downgrade)
…
Catalyst Pharmaceuticals: New Products In Proving Phase
…
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage…
Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)
…
GNW-Adhoc: Santheras Partner Catalyst Pharmaceuticals lanciert AGAMREE® (Vamorolon) in den Vereinigten Staaten
^* AGAMREE® ist von der U.S. FDA zugelassen und jetzt in den USA für die Behandlung von…
GNW-Adhoc: Santheras Partner Catalyst Pharmaceuticals lanciert AGAMREE® (Vamorolon) in den Vereinigten Staaten
^* AGAMREE® ist von der U.S. FDA zugelassen und jetzt in den USA für dieBehandlung von Duchenne-Muskeldystrophie (DMD) bei Patienten…
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
Pratteln, Switzerland, March 14, 2024 – Santhera Pharmaceuticals (SIX: SANN) is pleased to note the launch of AGAMREE® (vamorolone) for the…
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
CORAL GABLES, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage…